Details for New Drug Application (NDA): 213377
✉ Email this page to a colleague
NDA 213377 describes MESALAMINE, which is a drug marketed by Teva Pharms Usa, Alembic, Alkem Labs Ltd, Amta, Annora Pharma, Aurobindo Pharma Ltd, Mylan, Novast Labs, Sun Pharm, Zydus Pharms, Encube, G And W Labs Inc, Novitium Pharma, Padagis Israel, Actavis Mid Atlantic, Amneal, Amring Pharms, Quagen, Rising, Sandoz, Actavis Labs Fl, Sinotherapeutics Inc, and Teva Pharms Inc, and is included in thirty-three NDAs. It is available from thirty suppliers. Additional details are available on the MESALAMINE profile page.
The generic ingredient in MESALAMINE is mesalamine. There are twenty-eight drug master file entries for this compound. Thirty-eight suppliers are listed for this compound. Additional details are available on the mesalamine profile page.
The generic ingredient in MESALAMINE is mesalamine. There are twenty-eight drug master file entries for this compound. Thirty-eight suppliers are listed for this compound. Additional details are available on the mesalamine profile page.
Summary for 213377
| Tradename: | MESALAMINE |
| Applicant: | Annora Pharma |
| Ingredient: | mesalamine |
| Patents: | 0 |
Suppliers and Packaging for NDA: 213377
| Tradename | Generic Name | Dosage | NDA | Application Type | Supplier | National Drug Code | Package Code | Package |
|---|---|---|---|---|---|---|---|---|
| MESALAMINE | mesalamine | SUPPOSITORY;RECTAL | 213377 | ANDA | Camber Pharmaceuticals, Inc. | 31722-005 | 31722-005-30 | 5 PACKAGE in 1 CARTON (31722-005-30) / 6 SUPPOSITORY in 1 PACKAGE (31722-005-32) |
| MESALAMINE | mesalamine | SUPPOSITORY;RECTAL | 213377 | ANDA | Camber Pharmaceuticals, Inc. | 31722-005 | 31722-005-31 | 7 PACKAGE in 1 CARTON (31722-005-31) / 6 SUPPOSITORY in 1 PACKAGE (31722-005-32) |
Profile for product number 001
| Active Rx/OTC/Discontinued: | RX | Dosage: | SUPPOSITORY;RECTAL | Strength | 1GM | ||||
| Approval Date: | Mar 19, 2020 | TE: | AB | RLD: | No | ||||
Complete Access Available with Subscription
